2026-11-12 · By SEPT AI
The divergence between the QQQ and the DIA tells the story of the day. Money flowed into mega-cap technology and growth names while cyclical and industrial components weighed on the Dow. Small caps were hit hardest, with the Russell 2000 proxy closing near its session low of $278.04 after touching a high of $282.20 earlier in the day. The intraday reversal in IWM suggests risk appetite faded as the session progressed, even as the QQQ closed near its high of $694.56.
The session's sector performance reflected a clear risk-on rotation into technology and a retreat from broader market exposure. The QQQ's 1.15% gain stood in stark contrast to the DIA's 0.36% decline and IWM's 1.06% drop. This kind of narrow leadership—where large-cap tech carries the indices while the rest of the market lags—often signals underlying caution, consistent with the Fear & Greed reading of 28.
Speculative trading was on full display in the small-cap and micro-cap space. GP led all gainers with a staggering 146.49% surge to $1.23 on volume of 111.9 million shares, a massive spike that suggests a news-driven event or short squeeze. AIMD followed with a 118.47% gain to $1.06 on 76 million shares, and XLAB rose 116.19% to $2.27 on 54.1 million shares. These three names alone accounted for hundreds of millions of shares traded, indicating intense retail and momentum interest.
BGIN added 43.48% to $2.64, while ADVB gained 36.49% to $3.31 and OPRX climbed 32.39% to $8.87. PLBL rose 30.05% to $7.27, CWVX advanced 29.82% to $5.18, and CRWG gained 27.65% to $6.14. TGEN rose 26.86% to $2.22 and RETO added 25.36% to $7.76.
On the downside, SMX plunged 37.22% to $4.84, and ADIG dropped 36.48% to $9.82 on 5.66 million shares. GLAS fell 30.94% to $1.25, OMH lost 30.21% to $5.06, and KPLT declined 27.01% to $8.16. ARAI dropped 26.69% to $2.06 and CDNL fell 25.69% to $5.64 on 19.2 million shares.
Notably, NVDX and NVDG—both trading at $10.43—rose 23.87% and 23.58% respectively, suggesting leveraged or derivative products tied to Nvidia-related exposure saw heavy demand.
Key Earnings
Applied Materials was the marquee report of the day, posting fourth-quarter adjusted earnings of $4.16 per share and sales of $10.410 billion, both above analyst estimates of $4.05 and $10.299 billion. The semiconductor equipment maker's beat provided a tailwind for the tech-heavy QQQ.
Andersen Group delivered a standout quarter, reporting adjusted earnings of $2.39 per share against a $1.11 estimate, with revenue of $337.318 million topping the $333.636 million projection. Spire announced an increase to its quarterly dividend, raising it to $0.865 per share from $0.825, payable January 5 to shareholders of record as of December 11.
Several companies reported disappointing results. US Antimony posted third-quarter results that fell short of expectations and withdrew its guidance entirely. AnaptysBio reported earnings of $0.11 per share, well below the $0.51 consensus, with revenue of $30.274 million missing the $33.186 million estimate. Macrogenics posted a wider-than-expected loss of $0.34 per share against a $0.12 estimate, with revenue of $18.667 million falling far short of the $43.748 million projection. Arrowhead Pharma reported a fourth-quarter loss of $3.01 per share, missing the expected $1.61 loss, with revenue of $37.794 million below the $55.838 million estimate.
On the positive side, Sanara MedTech posted a profit of $0.15 per share, topping the $0.08 forecast, though revenue of $28.4 million fell short. Crescent Biopharma reported a wider loss of $0.90 per share but revenue of $3.117 million crushed the $312,500 estimate. VolitionRX posted a narrower-than-expected loss of 21 cents per share versus the 40-cent estimate, with revenue of $1.614 million exceeding the $706,500 projection. OptimumBank Holdings reported earnings of $0.30 per share, above the $0.27 estimate, with revenue of $19.617 million beating the $3.530 million projection.
CaliberCos narrowed its third-quarter loss to $0.49 per share as revenue reached $4.3 million, but the company cut its full-year 2026 sales guidance to $15 million to $17 million from a prior range of $18 million to $22 million. Health In Tech also reduced its full-year 2026 sales forecast to $30 million from $33 million after posting a wider quarterly loss.
There were no major economic data releases or Fed comments in the session. The market's focus remained squarely on earnings and individual stock catalysts.
Institutional and insider positioning data across recent months shows notable accumulation in several names. Regal Rexnord (RSG) stands out with 81 insider buys totaling approximately $1.05 billion, alongside Norwegian Cruise Line (NCLH), which has seen six insider buys worth $28.2 million. Uber Technologies has drawn three insider buys totaling $15.3 million, and MercadoLibre has seen three insider buys worth $1.2 million. Other names showing consistent insider accumulation include CECO, FBK, GBCI, L, NHI, and TSM, which has recorded 108 insider buys totaling approximately $1.0 million.
There was no significant cryptocurrency market data or news in today's session.
Friday's session will bring another wave of earnings reports, with the market continuing to digest the heavy flow of quarterly results. Investors will be watching whether the narrow leadership in large-cap technology can persist or whether the weakness in small caps and cyclicals spreads. The Fear & Greed Index at 28 suggests sentiment remains fragile, and any disappointment on the earnings front could exacerbate the divergence between the QQQ and the broader market. With no major economic data on the calendar, individual stock catalysts are likely to drive trading once again.
Access real-time market data, AI analysis, dark pool activity, and options flow.
Start Free Trial